Ramratnam et al. [92] reported that double-transgenic mice (SGLT1 knockdown with PRKAG2 mutation) have attenuated cardiac glycogen accumulation, cardiac hypertrophy, and LV dysfunction. This evidence concerns the gene SLC5A1 and cardiac hypertrophy.